A Multicenter, Randomized, Double-Blind, Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination Taken Orally for 8 Weeks in Adult Subjects with Essential Hypertension Who Are Inadequately Controlled on 16 mg Candesartan Cilexetil Monotherapy

Trial Profile

A Multicenter, Randomized, Double-Blind, Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination Taken Orally for 8 Weeks in Adult Subjects with Essential Hypertension Who Are Inadequately Controlled on 16 mg Candesartan Cilexetil Monotherapy

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 25 May 2017

At a glance

  • Drugs Candesartan cilexetil/nifedipine (Primary) ; Candesartan cilexetil
  • Indications Essential hypertension
  • Focus Registrational; Therapeutic Use
  • Sponsors Bayer; Bayer HealthCare
  • Most Recent Events

    • 16 Dec 2016 This trial has been completed in Spain.
    • 15 Dec 2016 This trial was completed in Germany (end date: 2016-09-28), according to European Clinical Trials Database.
    • 01 Dec 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top